SC sets aside NCLAT order on Dhanuka’s resolution plan for Orchid Pharma

HomeNews ArticlesSupreme Court

SC sets aside NCLAT order on Dhanuka’s resolution plan for Orchid Pharma

The apex court's ruling effectively gives the green signal to Dhanuka's plan for Orchid Pharma

IBC: 30-day grace period will hurt repayment discipline
UPI system payments glitch: Sebi knocks on RBI-regulated NPCI’s door
RBI moves unlikely to ease pain for India’s struggling NBFCs

CHENNAI: The Supreme Court of India has set aside a National Company Law Appellate Tribunal’s (NCLAT) order rejecting the resolution plan of Gurgaon-based Dhanuka Laboratories for the debt-ridden Chennai-based Orchid Pharma. The latest order, in an appeal filed by State Bank of India (SBI), is a green signal to Dhanuka Laboratories’ resolution plan, which was approved by the National Company Law Tribunal (NCLT) in June 2019, legal sources said.

The NCLAT, in November, 2019, had set aside the NCLT’s order, which approved the resolution plan of Dhanuka, observing that the resolution plan is less than the liquidation value, which is against the provisions of the Insolvency and Bankruptcy Code. Besides, it is against the principle of maximisation of assets of the corporate debtor, the Appellate Tribunal said in a petition filed by Accord Life Spec Pvt Ltd, an unsuccessful bidder for Orchid Pharma.

The Supreme Court division bench consisting of Justice Rohinton Fali Nariman and Justice S Ravindra Bhat, in the latest order observed that the NCLAT’s judgement has to be set aside in view of a recent Judgement where it was categorically held that no provision in the Insolvency and Bankruptcy Code or Regulations have been brought to the Court’s notice, under which the bid of any resolution applicant has to match liquidation value arrived at in the manner provided in the relevant regulations.

“Accordingly, the appeal is allowed and the judgement of the NCLAT is set aside,” said the order.

SBI, an important member in the Committee of Creditors (CoC), filed the appeal with the Supreme Court to set aside the NCLAT order, alleging that the Appellate Tribunal erred in overriding the commercial wisdom of the CoC. This was the second attempt to bring in an investor to save Orchid Pharma. Earlier, the NCLT has nullified a resolution plan by US-based Ingen Capital after it was approved, since the investor allegedly did not bring in money as per the norms.

Orchid Pharma owes around Rs 3,200 crore to a total of 24 banks. Accord, in its appeal at the NCLAT, alleged that Dhanuka’s actual resolution value proposed was Rs 570 crore as against liquidation value of Rs 1,309 crore.

The NCLT, in its order in June, 2019, noticed that according to the resolution professional’s explanation, while Dhanuka’s resolution plan value was Rs 570 crore, which is lower than the liquidation value of Rs 1,309 crore, Orchid Pharma had a cash and bank balance of Rs 321.98 crore. This and some other factors brought the plan value to around Rs 1,116.04 crore, close to the liquidation value.

It also said that since there is no other plan more feasible and viable than this plan and there being no mandate saying that the Resolution Plan value shall always be more than the liquidation value of Orchid Pharma in order to let the company remain as going concern and to close out the long drawn process, it is approving the resolution plan of Dhanuka Laboratories. Around 1407 employees are eking their livelihood by working in the company and if there is no solution, the immediate effect will be on the employees, it observed. Dhanuka is a manufacturer and exporter of oral cephalosporin APIs.

Source- Business Standard.